Boston Scientific Corporation

Boston Scientific Corporation (BSX) – Cardiology business is on fire

in , , on December 7, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Boston Scientific Corporation (BSX)

BSX experienced strong growth in its cardiovascular business. The revenue for this segment grew more than 30% for the quarter due to high sales of WATCHMAN, an implantable device that sits in the left atrial appendage of the heart to help reduce the risk of strokes.



– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages : 36

Release Information

  • Price


  • Released

    December 7, 2022

  • Last Updated

    December 8, 2022